Brand Institute announced its work with Celltrion Healthcare in developing the brand name VEGZELMA®, which was approved by the FDA on September 27, 2022. As a product, VEGZELMA® (bevacizumab-adcd) is the fourth bevacizumab biosimilar currently approved in the United States. VEGZELMA® is indicated for the treatment of patients with: Metastatic colorectal cancer; Recurrent or metastatic non-squamous non-small cell lung cancer; Recurrent glioblastoma; Metastatic renal cell carcinoma; Persistent, recurrent, or metastatic cervical cancer; and Epithelial ovarian, fallopian tube, or primary peritoneal cancer.